VanEck Associates’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $155M | Sell |
310,006
-35,746
| -10% | -$17.2M | 0.09% | 149 |
|
|
2026
Q1 | $170M | Sell |
345,752
-14,742
| -4% | -$8M | 0.13% | 145 |
|
|
2025
Q4 | $209M | Sell |
360,494
-410,280
| -53% | -$232M | 0.17% | 113 |
|
|
2025
Q3 | $374M | Buy |
770,774
+337,008
| +78% | +$157M | 0.35% | 64 |
|
|
2025
Q2 | $176M | Buy |
433,766
+43,051
| +11% | +$18M | 0.2% | 107 |
|
|
2025
Q1 | $194M | Sell |
390,715
-27,650
| -7% | -$15M | 0.25% | 100 |
|
|
2024
Q4 | $218M | Buy |
418,365
+68,927
| +20% | +$37.9M | 0.28% | 87 |
|
|
2024
Q3 | $201M | Buy |
349,438
+5,721
| +2% | +$3.39M | 0.25% | 99 |
|
|
2024
Q2 | $190M | Sell |
343,717
-31,057
| -8% | -$17.8M | 0.27% | 94 |
|
|
2024
Q1 | $218M | Buy |
374,774
+22,557
| +6% | +$12.7M | 0.33% | 81 |
|
|
2023
Q4 | $187M | Buy |
352,217
+339,013
| +2,568% | +$164M | 0.34% | 79 |
|
|
2023
Q3 | $6.68M | Sell |
13,204
-1,954
| -13% | -$1.04M | 0.01% | 428 |
|
|
2023
Q2 | $7.91M | Buy |
15,158
+991
| +7% | +$535K | 0.02% | 395 |
|
|
2023
Q1 | $8.16M | Buy |
14,167
+1,533
| +12% | +$864K | 0.02% | 382 |
|
|
2022
Q4 | $6.96M | Sell |
12,634
-190
| -1% | -$101K | 0.02% | 404 |
|
|
2022
Q3 | $6.5M | Sell |
12,824
-333
| -3% | -$186K | 0.02% | 383 |
|
|
2022
Q2 | $7.15M | Sell |
13,157
-2,390
| -15% | -$1.32M | 0.02% | 382 |
|
|
2022
Q1 | $9.18M | Sell |
15,547
-1,470
| -9% | -$844K | 0.02% | 378 |
|
|
2021
Q4 | $11.4M | Sell |
17,017
-172,193
| -91% | -$108M | 0.03% | 349 |
|
|
2021
Q3 | $108M | Sell |
189,210
-5,431
| -3% | -$2.98M | 0.27% | 94 |
|
|
2021
Q2 | $98.2M | Buy |
194,641
+189,478
| +3,670% | +$89.4M | 0.23% | 112 |
|
|
2021
Q1 | $2.36M | Buy |
5,163
+201
| +4% | +$95.9K | 0.01% | 572 |
|
|
2020
Q4 | $2.31M | Buy |
4,962
+875
| +21% | +$410K | 0.01% | 520 |
|
|
2020
Q3 | $1.8M | Sell |
4,087
-6,181
| -60% | -$2.55M | 0.01% | 516 |
|
|
2020
Q2 | $3.72M | Sell |
10,268
-3,139
| -23% | -$1.05M | 0.01% | 379 |
|
|
2020
Q1 | $3.8M | Sell |
13,407
-2,923
| -18% | -$922K | 0.02% | 368 |
|
|
2019
Q4 | $5.3M | Sell |
16,330
-4,257
| -21% | -$1.29M | 0.02% | 361 |
|
|
2019
Q3 | $6M | Buy |
20,587
+646
| +3% | +$185K | 0.03% | 306 |
|
|
2019
Q2 | $5.86M | Buy |
19,941
+1,749
| +10% | +$482K | 0.03% | 296 |
|
|
2019
Q1 | $4.98M | Sell |
18,192
-4,689
| -20% | -$1.17M | 0.02% | 304 |
|
|
2018
Q4 | $5.12M | Buy |
22,881
+2,082
| +10% | +$488K | 0.03% | 302 |
|
|
2018
Q3 | $5.08M | Buy |
20,799
+1,600
| +8% | +$368K | 0.02% | 320 |
|
|
2018
Q2 | $3.98M | Buy |
+19,199
| New | +$4.08M | 0.02% | 339 |
|
Other funds holding TMO
VanEck Associates's TMO Position: Q2 2026 in Review
VanEck Associates reduced its Thermo Fisher Scientific (TMO) stake by 10% in Q2 2026, selling an estimated $17.2M and leaving 310,006 shares worth $155M. The position accounts for 0.09% of the portfolio, ranked #149.
VanEck Associates first reported a position in TMO in Q2 2018 and has held it in 33 quarters since. The position peaked at $374M in Q3 2025. 2,602 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- VanEck Associates held 310,006 shares of Thermo Fisher Scientific worth $155M as of Q2 2026.
- VanEck Associates sold 35,746 Thermo Fisher Scientific shares in Q2 2026, an estimated $17.2M.
- Thermo Fisher Scientific made up 0.09% of VanEck Associates's portfolio in Q2 2026, its #149 holding.
- VanEck Associates first reported a position in Thermo Fisher Scientific in Q2 2018 and has held it in 33 quarters since.
- VanEck Associates's Thermo Fisher Scientific position peaked at $374M in Q3 2025.
- 2,602 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.